<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02896413</url>
  </required_header>
  <id_info>
    <org_study_id>4-2015-0453</org_study_id>
    <nct_id>NCT02896413</nct_id>
  </id_info>
  <brief_title>The Effects of Perioperative Dexmedetomidine Administration on Immune Suppression and Outcomes in Patients With Uterine Cancer Undergoing Radical Resection</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Surgical stress and anesthesia may cause immunosuppression in immunocompromised cancer&#xD;
      patients. The natural killer (NK) cell is a critical part of anti-tumor immunity.&#xD;
      Dexmedetomidine has sympatholytic effect and preserves NK cell function. This study&#xD;
      investigate the effect of dexmedetomidine on immune suppression and postoperative outcomes in&#xD;
      patients undergoing uterine cancer resection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2, 2016</start_date>
  <completion_date type="Actual">October 24, 2018</completion_date>
  <primary_completion_date type="Actual">October 24, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>natural killer cell cytotoxicity</measure>
    <time_frame>1 minute before surgery</time_frame>
    <description>Natural killer cell cytotoxicity is measured with NK Vue Kit™(ATGen, Gyeonggi-do, Korea).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>natural killer cell cytotoxicity</measure>
    <time_frame>postoperative day 1</time_frame>
    <description>Natural killer cell cytotoxicity is measured with NK Vue Kit™(ATGen, Gyeonggi-do, Korea).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>natural killer cell cytotoxicity</measure>
    <time_frame>postoperative day 3</time_frame>
    <description>Natural killer cell cytotoxicity is measured with NK Vue Kit™(ATGen, Gyeonggi-do, Korea).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>natural killer cell cytotoxicity</measure>
    <time_frame>postoperative day 5</time_frame>
    <description>Natural killer cell cytotoxicity is measured with NK Vue Kit™(ATGen, Gyeonggi-do, Korea).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>inflammatory response</measure>
    <time_frame>1 minute before surgery</time_frame>
    <description>inflammatory response is assessed by measuring levels of proinflammatory cytokines.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory response</measure>
    <time_frame>postoperative day 1</time_frame>
    <description>inflammatory response is assessed by measuring levels of proinflammatory cytokines.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory response</measure>
    <time_frame>postoperative day 3</time_frame>
    <description>inflammatory response is assessed by measuring levels of proinflammatory cytokines.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory response</measure>
    <time_frame>postoperative day 5</time_frame>
    <description>inflammatory response is assessed by measuring levels of proinflammatory cytokines.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Uterine Cancer</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dexmedetomidine infusion (0.4 mcg/kg/h) from immediately after anesthetic induction to 24 h after surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% saline infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine group</intervention_name>
    <description>dexmedetomidine infusion (0.4 mcg/kg/h) from immediately after anesthetic induction to 24 h after surgery</description>
    <arm_group_label>Dexmedetomidine Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control group</intervention_name>
    <description>0.9% saline infusion</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patient between 20 and 70 of age with ASA physical status Ⅰ-Ⅲ&#xD;
&#xD;
          -  patient scheduled for uterine cancer surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ASA physical status Ⅳ&#xD;
&#xD;
          -  severe hepatorenal disease&#xD;
&#xD;
          -  infection&#xD;
&#xD;
          -  metastasis to other organ&#xD;
&#xD;
          -  problem with communication&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institue, Yonsei Universiy College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>September 6, 2016</study_first_submitted>
  <study_first_submitted_qc>September 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2016</study_first_posted>
  <last_update_submitted>May 3, 2021</last_update_submitted>
  <last_update_submitted_qc>May 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

